# Expert Assessment: ENS Dysfunction as Therapeutic Target in PD
## Druggability Assessment
The hypothesis identifies multiple druggable nodes: α-synuclein aggregation, gut motility dysfunction, SIBO/dysbiosis, and enteric glial reactivity. The gut offers a practical advantage over CNS—direct luminal access, better bioavailability for oral agents, and ability to monitor therapeutic response via stool samples and breath tests.
## Existing Clinical Candidates
**GLP-1 Receptor Agonists** represent the most advanced translational effort. Exenatide (NCT04216320), liraglutide, and semaglutide have shown signals in Phase II PD trials, with enteric anti-inflammatory effects potentially contributing to efficacy. NLY01 (Denali/Neomorph) is being developed specifically for this mechanism.
**α-synuclein antibodies** including prasinezumab (Roche/Prothena) and bextragene (Biogen) target systemic SNCA—gut exposure is plausible given moderate antibody biodistribution. Semorinemab (Genentech) failed Phase II for motor symptoms but may have gut-relevant effects worth investigating.
**Probiotic formulations** (e.g., Ecoderma/Enterome's EB 8018 targeting adherent-invasive E. coli) are in early clinical testing for PD-related dysbiosis. This approach is attractive for safety but faces efficacy hurdles.
**Microbiome modulation** via rifaximin for SIBO (already prescribed off-label) and emerging FMT trials (NCT03841223) represent low-cost, near-term interventions.
## Competitive Landscape
AbbVie, Roche, and Prothena dominate α-synuclein targeting. GLP-1 repurposing is crowded but low-cost. The microbiome angle remains largely unpatented and fragmented.
## Timeline & Cost Estimate
Oral gut-targeted therapies: $50-100M, 4-6 years. CNS-penetrant follow-ons would add $200-300M and 3+ years.
## Key Safety Concern
Enteric immune modulation risks infection (SIBO antibiotics), gastrointestinal adverse events, and unintended CNS effects if systemically absorbed GLP-1 agonists alter neuroinflammation beyond intended targets.